Celltrion is a fully integrated biopharmaceutical company dedicated to delivering innovative and affordable medications to improve patients’ access to advanced therapies. Pioneering monoclonal antibody (mAb) biosimilars, built on a legacy of trust, we are advancing antibody-based biologics to address unmet medical needs. Our end-to-end capabilities - from R&D to distribution - ensure efficiency, quality, and innovation at every stage, bringing life-changing therapies to patients worldwide. Partnering with purpose, we are committed to driving customer intimacy to co-creating value at every touchpoint across the care journey. #BuiltonTrustTowardInnovation
For guidelines: https://bit.ly/4jv2wf2
MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across Oncology, Respiratory, Cardiovascular, Renal and Metabolic Diseases, and Infection and Vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centres, with additional sites in Cambridge, UK and South San Francisco, CA.
For more information, please visit www.medimmune.com
SOTIO Biotech (SOTIO) is a clinical-stage biopharmaceutical company advancing a focused pipeline of next-generation antibody-drug conjugates (ADCs) for solid tumors. The company is pursuing targeted therapies for cancers with significant unmet need and broad expansion potential.
SOTIO’s two lead ADC programs, SOT106 and SOT109, are potential best-in-class therapies designed to rapidly advance to clinical proof of concept. SOT109, currently in a Phase 1/2 study for colorectal cancer, has received Fast Track Designation (FTD) from the U.S. FDA. SOT106, targeting LRRC15 for sarcoma and other solid tumors, has received both Orphan Drug Designation (ODD) and FTD from the U.S. FDA.
The broader pipeline also includes SOT201, a next-generation PD-1-targeting immunocytokine, currently being evaluated in the Phase 1 VICTORIA-01 study in patients with solid tumors.
SOTIO is a member of the PPF Group.